Amgen launches biosimilar for the treatment of inflammatory diseases
[caption id="attachment_9277" align="aligncenter" width="747"]
Press Release[/caption]
S?O PAULO, February 3, 2020 / PRNewswire / - Amgen, one of the largest biotechnology companies in the world, announces the launch and commercialization of the first biosimilar medicine of the adalimumab molecule available in Brazil.?AMGEVITA? was approved by the National Health Surveillance Agency (ANVISA), with indication for the treatment of several inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, ulcerative colitis or ulcerative colitis, plaque psoriasis, uveitis and hydradenitis suppurative.?These clinical conditions affect millions of Brazilians - counting only those who live with rheumatoid arthritis, for example, there are more than 2 million people in the country?1?. ?
"The arrival of this medicine in the health systems is very significant for Brazilian patients who deal with chronic inflammatory diseases and who now have a new option for access to innovative treatment with high quality biological medicines", comments Dr. Valder?lio Azevedo, doctor rheumatologist at Hospital de Cl?nicas, Universidade Federal do Paran?. ?
The commercialization of AMGEVITA? represents a possibility to reduce the signs and symptoms of chronic inflammatory diseases, in addition to bringing the benefit of clinical remission and inhibiting the progression of these pathologies.?"Amgen's purpose is to make high-cost biological therapies for patients with serious illnesses accessible so that the benefit reaches the patient providing greater physical capacity and quality of life", highlights Amgen's medical director in Brazil,?Tatiana Castello Branco?.
The drug was approved by ANVISA in April 2019 based on a robust clinical and technical dossier that proves biosimilarity with the reference biological product, through in vitro analyzes, pharmacokinetics and clinical information, including results of phase III clinical studies. conducted with patients with moderate to severe psoriasis and rheumatoid arthritis.
Amgen has 40 years of expertise in the development, production and availability of high quality biological medicines.?The company is committed to innovation in biotechnology for health, with several biological therapies in its portfolio used in the areas of oncology, hematology and inflammatory diseases.
More information at:?www.biossimilaresamgen.com.br?.
1??Brazilian Society of Rheumatology.?Available at?https://saude.abril.com.br/medicina/maior-causa-de-morte-em-quem-tem-artrite-reumatoide/?.?Accessed on December 3, 2019.
SOURCE Amgen
SOURCE Amgen
Press Release[/caption]
S?O PAULO, February 3, 2020 / PRNewswire / - Amgen, one of the largest biotechnology companies in the world, announces the launch and commercialization of the first biosimilar medicine of the adalimumab molecule available in Brazil.?AMGEVITA? was approved by the National Health Surveillance Agency (ANVISA), with indication for the treatment of several inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, ulcerative colitis or ulcerative colitis, plaque psoriasis, uveitis and hydradenitis suppurative.?These clinical conditions affect millions of Brazilians - counting only those who live with rheumatoid arthritis, for example, there are more than 2 million people in the country?1?. ?
"The arrival of this medicine in the health systems is very significant for Brazilian patients who deal with chronic inflammatory diseases and who now have a new option for access to innovative treatment with high quality biological medicines", comments Dr. Valder?lio Azevedo, doctor rheumatologist at Hospital de Cl?nicas, Universidade Federal do Paran?. ?
The commercialization of AMGEVITA? represents a possibility to reduce the signs and symptoms of chronic inflammatory diseases, in addition to bringing the benefit of clinical remission and inhibiting the progression of these pathologies.?"Amgen's purpose is to make high-cost biological therapies for patients with serious illnesses accessible so that the benefit reaches the patient providing greater physical capacity and quality of life", highlights Amgen's medical director in Brazil,?Tatiana Castello Branco?.
The drug was approved by ANVISA in April 2019 based on a robust clinical and technical dossier that proves biosimilarity with the reference biological product, through in vitro analyzes, pharmacokinetics and clinical information, including results of phase III clinical studies. conducted with patients with moderate to severe psoriasis and rheumatoid arthritis.
Amgen has 40 years of expertise in the development, production and availability of high quality biological medicines.?The company is committed to innovation in biotechnology for health, with several biological therapies in its portfolio used in the areas of oncology, hematology and inflammatory diseases.
More information at:?www.biossimilaresamgen.com.br?.
1??Brazilian Society of Rheumatology.?Available at?https://saude.abril.com.br/medicina/maior-causa-de-morte-em-quem-tem-artrite-reumatoide/?.?Accessed on December 3, 2019.
SOURCE Amgen
SOURCE Amgen
